Kelvin A Moses1, Heather Orom2, Alicia Brasel2, Jacquelyne Gaddy3, Willie Underwood4. 1. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN. Electronic address: kelvin.a.moses@vanderbilt.edu. 2. Department of Community Health and Health Behavior, University at Buffalo, Buffalo, NY. 3. Loyola University Chicago Stritch School of Medicine, Chicago, IL. 4. Department of Community Health and Health Behavior, University at Buffalo, Buffalo, NY; Department of Urology, Roswell Park Cancer Institute, Buffalo, NY.
Abstract
OBJECTIVE: African-American (AA) men have excess mortality from prostate cancer compared with White men, which has remained unchanged over several decades. The purpose of this study is to determine if race/ethnicity is an independent predictor of receipt of any definitive treatment vs. watchful waiting/active surveillance (WW/AS). METHODS AND MATERIALS: Men diagnosed with prostate cancer from 2004 to 2011 were identified from the Surveillance, Epidemiology, and End-Results program. Multinomial logistic regression analysis was performed to determine the relative risk ratio (RRR) of receipt of radical prostatectomy (RP), external beam radiation therapy (RT), brachytherapy, cryotherapy, or combination therapy vs. WW/AS. RESULTS: Compared with White men, AA men were significantly less likely to receive RP (RRR = 0.53, P<0.001), brachytherapy (RRR = 0.72, P<0.001), cryotherapy (RRR = 0.84, P = 0.001), and combination therapy (RRR = 0.70, P<0.001), and more likely to receive RT (RRR = 1.03, P = 0.041) vs. AS/WW. Hispanic men were significantly less likely to receive RP (RRR = 0.84, P<0.001) and brachytherapy (RRR = 0.77, P<0.001), and more likely to receive RT (RRR = 1.08, P<0.001), and cryotherapy (RRR = 1.19, P = 0.005) vs. AS/WW compared with White men. CONCLUSIONS: The disparate risk of receiving definitive treatment among AA and Hispanic men represents a significant public health issue that requires efforts to improve physician education, increase cultural competency, and ensure equitable access.
OBJECTIVE: African-American (AA) men have excess mortality from prostate cancer compared with White men, which has remained unchanged over several decades. The purpose of this study is to determine if race/ethnicity is an independent predictor of receipt of any definitive treatment vs. watchful waiting/active surveillance (WW/AS). METHODS AND MATERIALS: Men diagnosed with prostate cancer from 2004 to 2011 were identified from the Surveillance, Epidemiology, and End-Results program. Multinomial logistic regression analysis was performed to determine the relative risk ratio (RRR) of receipt of radical prostatectomy (RP), external beam radiation therapy (RT), brachytherapy, cryotherapy, or combination therapy vs. WW/AS. RESULTS: Compared with White men, AA men were significantly less likely to receive RP (RRR = 0.53, P<0.001), brachytherapy (RRR = 0.72, P<0.001), cryotherapy (RRR = 0.84, P = 0.001), and combination therapy (RRR = 0.70, P<0.001), and more likely to receive RT (RRR = 1.03, P = 0.041) vs. AS/WW. Hispanic men were significantly less likely to receive RP (RRR = 0.84, P<0.001) and brachytherapy (RRR = 0.77, P<0.001), and more likely to receive RT (RRR = 1.08, P<0.001), and cryotherapy (RRR = 1.19, P = 0.005) vs. AS/WW compared with White men. CONCLUSIONS: The disparate risk of receiving definitive treatment among AA and Hispanic men represents a significant public health issue that requires efforts to improve physician education, increase cultural competency, and ensure equitable access.
Authors: Joseph R Betancourt; Alexander R Green; J Emilio Carrillo; Owusu Ananeh-Firempong Journal: Public Health Rep Date: 2003 Jul-Aug Impact factor: 2.792
Authors: David I Chu; Daniel M Moreira; Leah Gerber; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Mohamed H Kamel; Milan Bimali; Mahmoud I Khalil; Ehab Eltahawy; LJoseph Su; Nabil K Bissada; Rodney Davis Journal: Int Urol Nephrol Date: 2019-03-06 Impact factor: 2.370
Authors: Craig Evan Pollack; Katrina A Armstrong; Nandita Mitra; Xinwei Chen; Katelyn R Ward; Archana Radhakrishnan; Michelle S Wong; Justin E Bekelman; Charles C Branas; Karin V Rhodes; David T Grande Journal: Cancer Date: 2017-07-20 Impact factor: 6.860
Authors: Francisco A Montiel Ishino; Emmanuel A Odame; Kevin Villalobos; Claire Rowan; Martin Whiteside; Hadii Mamudu; Faustine Williams Journal: Am J Mens Health Date: 2021 Nov-Dec
Authors: Spyridon P Basourakos; Michael Tzeng; Patrick J Lewicki; Krishnan Patel; Bashir Al Hussein Al Awamlh; Siv Venkat; Jonathan E Shoag; Michael A Gorin; Christopher E Barbieri; Jim C Hu Journal: Front Oncol Date: 2021-05-28 Impact factor: 6.244
Authors: Carolyn K Kan; Muhammad M Qureshi; Apar Gupta; Ankit Agarwal; Gretchen A Gignac; B Nicolas Bloch; Nicholas Thoreson; Ariel E Hirsch Journal: Adv Radiat Oncol Date: 2017-12-13